Rallybio

RLYB · NASDAQ

$16.38+$0.03 (+0.18%)TodayMarket closed · Oct 20, 4:10 PM ET

Prev close $16.35

Latest news

Press releaseJul 21, 2:53 PM ETPRNewswire
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?
Press releaseJul 20, 3:21 PM ETPRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB
Press releaseJun 9, 1:19 PM ETPRNewswire
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?
Press releaseJun 2, 3:48 PM ETBusiness Wire
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
Press releaseJun 2, 12:15 PM ETPRNewswire
Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders
Press releaseJun 1, 12:27 PM ETBusiness Wire
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
Press releaseJun 1, 8:00 AM ETBusiness Wire
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Press releaseApr 9, 3:29 PM ETPRNewswire
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
Press releaseApr 6, 2:38 PM ETPRNewswire
Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders?
Press releaseMar 6, 11:15 AM ETPRNewswire
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?
Press releaseMar 4, 11:53 AM ETBusiness Wire
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
NewsMar 2, 4:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseMar 2, 3:56 PM ETPRNewswire
Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders?
NewsMar 2, 12:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsMar 2, 10:51 AM ETVandana Singh
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism
Press releaseMar 2, 10:49 AM ETBusiness Wire
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders
Press releaseMar 2, 8:00 AM ETBusiness Wire
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement
Press releaseFeb 17, 8:00 AM ETBusiness Wire
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement
Press releaseFeb 3, 4:05 PM ETBusiness Wire
Rallybio Announces Reverse Stock Split of Common Stock
NewsNov 6, 8:25 AM ET
Rallybio Q3 EPS $0.36 Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate
Press releaseNov 6, 8:00 AM ETBusiness Wire
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
NewsOct 23, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseSep 25, 8:00 AM ETBusiness Wire
Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
NewsSep 23, 5:07 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseSep 3, 8:00 AM ETBusiness Wire
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
Press releaseAug 7, 8:00 AM ETBusiness Wire
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
NewsJul 8, 9:44 AM ETVandana Singh
Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
Press releaseJul 8, 8:00 AM ETBusiness Wire
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
Press releaseJul 8, 8:00 AM ETGlobe Newswire
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Press releaseJun 12, 8:00 AM ETBusiness Wire
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
NewsJun 4, 1:08 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseMay 8, 8:00 AM ETBusiness Wire
Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates
Press releaseApr 29, 8:00 AM ETBusiness Wire
Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference
NewsMar 18, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseMar 13, 8:00 AM ETBusiness Wire
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Press releaseNov 7, 8:00 AM ETBusiness Wire
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
NewsOct 29, 8:20 AM ET
Rallybio Announces Approval Of Clinical Trial Applications For Phase 2 Trial Of RLYB212 In Pregnant Women At Higher Risk Of Alloimmunization And FNAIT
Press releaseOct 29, 8:00 AM ETBusiness Wire
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYB

Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Shareholder Alert: Ademi LLP investigates whether Rallybio Corporation is obtaining a Fair Price for Public Shareholders

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders

Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement

Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?

Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders?

Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders?

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

12 Health Care Stocks Moving In Monday's After-Market Session

Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders?

12 Health Care Stocks Moving In Monday's Intraday Session

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism

RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders

Rallybio Corporation and Candid Therapeutics Announce Merger Agreement

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Rallybio Announces Reverse Stock Split of Common Stock

Rallybio Q3 EPS $0.36 Beats $(0.21) Estimate, Sales $212.000K Beat $66.667K Estimate

Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates

12 Health Care Stocks Moving In Thursday's After-Market Session

Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

12 Health Care Stocks Moving In Tuesday's After-Market Session

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates

Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

12 Health Care Stocks Moving In Wednesday's Intraday Session

Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates

Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference

12 Health Care Stocks Moving In Tuesday's After-Market Session

Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates

Rallybio Announces Approval Of Clinical Trial Applications For Phase 2 Trial Of RLYB212 In Pregnant Women At Higher Risk Of Alloimmunization And FNAIT

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT